Straits Times Index
3,300.85 +8.16 (+0.25%) Nikkei
38,282.19 +8.14 (+0.02%) Hang Seng
18,029.12 +266.09 (+1.50%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,318.93 -2,428.62 (-4.06%) CMC Crypto 200
1,256.38 -82.69 (-8.79%)
Palatin Technologies, Inc. (PTN)
After hours:
| Previous close | 1.8600 |
| Open | 1.8600 |
| Bid | 1.8400 x 1300 |
| Ask | 1.8900 x 1000 |
| Day's range | 1.8114 - 1.9500 |
| 52-week range | 1.4300 - 5.6500 |
| Volume | |
| Avg. volume | 642,836 |
| Market cap | 30.175M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET. To register, click here.
- PR Newswire
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS).
- PR Newswire
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).
